Get the Stockscreener App
3.49
2.35%
0.08
After Hours:
3.50
0.010
+0.29%
Xeris Biopharma Holdings Inc stock is traded at $3.49, with a volume of 1.49M.
It is up +2.35% in the last 24 hours and up +14.05% over the past month.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.
See More
Previous Close:
$3.41
Open:
$3.35
24h Volume:
1.49M
Relative Volume:
0.98
Market Cap:
$520.29M
Revenue:
$181.41M
Net Income/Loss:
$-59.56M
P/E Ratio:
-6.7115
EPS:
-0.52
Net Cash Flow:
$-38.83M
1W Performance:
+6.40%
1M Performance:
+14.05%
6M Performance:
+66.99%
1Y Performance:
+73.63%
1-Day Range:
$3.35
$3.569
1-Week Range:
$3.17
$3.569
52-Week Range:
$1.69
$3.87
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
Name
Xeris Biopharma Holdings Inc
Sector
Industry
Phone
844-445-5704
Address
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Compare XERS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
3.49 | 520.29M | 181.41M | -59.56M | -38.83M | -0.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-28-24 | Initiated | Oppenheimer | Outperform |
| Aug-28-23 | Initiated | Craig Hallum | Buy |
| Oct-21-22 | Initiated | Jefferies | Buy |
| Apr-28-22 | Initiated | Craig Hallum | Buy |
| Nov-17-21 | Initiated | SVB Leerink | Outperform |
| Oct-29-21 | Initiated | H.C. Wainwright | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-18-20 | Initiated | Piper Sandler | Overweight |
| Jul-16-18 | Initiated | Jefferies | Buy |
| Jul-16-18 | Initiated | Leerink Partners | Outperform |
| Jul-16-18 | Initiated | RBC Capital Mkts | Outperform |
View All
Xeris Biopharma Holdings Inc Stock (XERS) Latest News
Applied Therapeutics Appoints John H. Johnson as Executive Chairman - The Manila Times
Xeris Biopharma (NASDAQ:XERS) Shares Up 5.2%What's Next? - MarketBeat
Quantbot Technologies LP Purchases Shares of 15,425 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Walleye Capital LLC Purchases Shares of 1,121,738 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Invests $237,000 in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
XERS (Xeris Biopharma Holdings) Revenue : $187.4 Mil (TTM As of Sep. 2024) - GuruFocus.com
Xeris Biopharma Holdings (FRA:2B30) Other Long Term Assets : €4.9 Mil (As of Sep. 2024) - GuruFocus.com
XERS (Xeris Biopharma Holdings) Other Stockholders Equity : $0.0 Mil (As of Sep. 2024) - GuruFocus.com
XERS (Xeris Biopharma Holdings) EPS (Diluted) : $-0.44 (TTM As of Sep. 2024) - GuruFocus.com
XERS (Xeris Biopharma Holdings) GF Score : 75/100 (As of Nov. 26, 2024) - GuruFocus.com
XERS (Xeris Biopharma Holdings) Accounts Payable : $7.5 Mil (As of Sep. 2024) - GuruFocus.com
GSA Capital Partners LLP Sells 578,313 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference - Business Wire
GSA Capital Partners LLP Trims Stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - MarketBeat
XERS (Xeris Biopharma Holdings) Cash-to-Debt : 0.26 (As of Sep. 2024) - GuruFocus.com
XERS (Xeris Biopharma Holdings) Shares Outstanding (EOP) : 149.0 Mil (As of Sep. 2024) - GuruFocus.com
XERS (Xeris Biopharma Holdings) Other Current Liabilities : $34.8 Mil (As of Sep. 2024) - GuruFocus.com
Analysts Expect Breakeven For Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Before Long - Yahoo Finance
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS): When Will It Breakeven? - Simply Wall St
HC Wainwright Forecasts Reduced Earnings for Xeris Biopharma - Defense World
Wealth Enhancement Advisory Services LLC Invests $35,000 in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
FY2024 EPS Estimate for Xeris Biopharma Raised by Analyst - Defense World
HC Wainwright Forecasts Higher Earnings for Xeris Biopharma - MarketBeat
Xeris Biopharma (NASDAQ:XERS) Rating Lowered to Neutral at Piper Sandler - Defense World
Xeris Biopharma (NASDAQ:XERS) Stock Price Expected to Rise, HC Wainwright Analyst Says - Defense World
HC Wainwright Forecasts Weaker Earnings for Xeris Biopharma - MarketBeat
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Xeris Biopharma posts record revenue in Q3 2024 - Investing.com India
Earnings call: Xeris Biopharma posts record revenue in Q3 2024 By Investing.com - Investing.com Nigeria
Xeris Biopharma Holdings Inc (XERS) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance
Xeris Biopharma Holdings Inc (XERS) Q3 2024 Earnings Call Highli - GuruFocus.com
Xeris Biopharma Reports Record Third Quarter Revenue - TipRanks
Xeris Biopharma Holdings Inc (XERS) Quarterly 10-Q Report - Quartzy
Xeris raises revenue outlook on strong 3rd-quarter results - Crain's Chicago Business
Xeris Biopharma Reports Third Quarter 2024 Financial Results - BioSpace
Xeris Biopharma (XERS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Xeris Biopharma Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Xeris Biopharma (XERS) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Xeris Biopharma Holdings Inc Reports Q3 2024 Revenue of $54.3M, Beating Estimates; EPS Misses at ($0.11) - GuruFocus.com
Xeris Biopharma: Q3 Earnings Snapshot - San Francisco Chronicle
Xeris Biopharma (XERS) to Release Earnings on Friday - Defense World
Xeris Biopharma (XERS) Scheduled to Post Quarterly Earnings on Friday - MarketBeat
Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024 - BioSpace
Xeris Biopharma Holdings: Promising Pipeline And Strategic Partnerships Make It Attractive - Seeking Alpha
SG Americas Securities LLC Raises Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
The Manufacturers Life Insurance Company Buys 5,291 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
The Xeris Biopharma Holdings Inc (XERS) had a good session last reading, didn’t it? - US Post News
Dimensional Fund Advisors LP Sells 6,437 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma Holdings Inc Stock (XERS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Xeris Biopharma Holdings Inc Stock (XERS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Schmid John P. | Director |
Aug 12 '24 |
Buy |
2.25 |
4,515 |
10,147 |
25,200 |
| Schmid John P. | Director |
Aug 09 '24 |
Buy |
2.37 |
4,285 |
10,134 |
20,685 |
| Schmid John P. | Director |
May 10 '24 |
Buy |
1.91 |
5,400 |
10,314 |
16,400 |
| JOHNSON JOHN | Director |
Mar 18 '24 |
Option Exercise |
1.99 |
215,600 |
429,044 |
751,412 |
| Schmid John P. | Director |
Mar 14 '24 |
Buy |
2.16 |
4,500 |
9,720 |
11,000 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):